At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 115 enrolled
Drug / intervention
Canakinumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 54-week, Phase II, Multi-center, Open-label Extension Study to Evaluate the Efficacy, Safety and Tolerability of ACZ885 (Anti-interleukin-1B Monoclonal Antibody) in Patients With Rheumatoid Arthritis
In Brief
A Phase 2 clinical trial evaluating Canakinumab for Rheumatoid Arthritis. Completed, enrolled 115 participants across 51 sites in 9 countries.
Detailed Summary
This study will assess the long-term safety and tolerability of ACZ885 in patients with rheumatoid arthritis, as well as long-term efficacy, long-term preservation and/or improvement of joint structure and bone mineral density, and long term maintenance of health-related quality of life.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesBelgium, Germany, Italy, Netherlands, Russia, Spain, Switzerland, Turkey (Türkiye), United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2007
First PostedNov 2007
Primary CompletionAug 2009
TodayJul 2026
First PostedNov 7, 2007
Enrollment StartOct 11, 2007
Primary CompletionAug 13, 2009
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 18.7 years ago
Interventions
Canakinumabdrug
Canakinumab